Pharmaceutical company to sell Cold-Eeze lozenge brand


Save Story

Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

DOYLESTOWN, Pa. (AP) — The Pennsylvania-based maker of Cold-Eeze throat lozenges has announced that it has sold the brand to another pharmaceutical company for $50 million.

Under the terms of the deal, Canonsburg-based Mylan has agreed to purchase a majority of the Doylestown-based ProPhase Labs Inc.'s assets and other rights related to the Cold-Eeze brand.

ProPhase has retained ownership of its Lebanon County plant and will continue working on developing dietary supplements and a male sex drive pill.

The company reported sales of around $20 million in its latest annual report. ProPhase operated at a loss in eight of the past 10 years.

Mylan has been the object of criticism since the company hiked up the price of the EpiPen, an emergency epinephrine injector used by people with severe allergies.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Most recent Business stories

Related topics

The Associated Press

    STAY IN THE KNOW

    Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the KSL.com Trending 5.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.
    Newsletter Signup

    KSL Weather Forecast

    KSL Weather Forecast
    Play button